Igreja Ana Carolina de Souza Machado, Mesquita Kleyton de Carvalho, Cowper Shawn Edwin, Costa Izelda Maria Carvalho
Hospital Universitário de Brasília, Federal District, Brazil.
An Bras Dermatol. 2012 Jul-Aug;87(4):597-607. doi: 10.1590/s0365-05962012000400013.
Nephrogenic systemic fibrosis is a chronic, progressive condition that develops in some patients with renal impairment after exposure to gadolinium-based contrast agents used in magnetic resonance imaging. Thickening of the skin is typical, usually affecting the extremities. Visceral organs can also be affected. The diagnosis of the disease requires careful clinicopathological correlation. Treatment aims at restoring renal function, which is associated with delayed progression and, eventually, remission of skin changes. Reduction and prevention of nephrogenic systemic fibrosis cases are based on limiting the use of gadolinium-based contrast agents in patients with kidney disorders (especially in patients with advanced renal failure at stages 4 and 5), and restricting their use to situations in which they are essential to diagnosis/follow-up. Other than limiting exposure to gadolinium based contrast agents, no effective preventive methods have been reported. Due to increased awareness about the disease among radiologists and nephrologists, the incidence of nephrogenic systemic fibrosis is declining.
肾源性系统性纤维化是一种慢性进行性疾病，在一些肾功能损害患者接触用于磁共振成像的钆基造影剂后发生。皮肤增厚很典型，通常影响四肢。内脏器官也可能受到影响。该疾病的诊断需要仔细的临床病理相关性分析。治疗旨在恢复肾功能，这与疾病进展延迟以及最终皮肤病变缓解相关。减少和预防肾源性系统性纤维化病例的发生基于限制在肾脏疾病患者（尤其是4期和5期晚期肾衰竭患者）中使用钆基造影剂，并将其使用限制在对诊断/随访至关重要的情况下。除了限制接触钆基造影剂外，尚未报道有效的预防方法。由于放射科医生和肾病学家对该疾病的认识提高，肾源性系统性纤维化的发病率正在下降。
